8-K: CytoSorbents Reports Mixed 2025 Results, Eyes 2026 Breakeven

CytoSorbents Corporation announced its full year and fourth quarter 2025 financial results, showing modest revenue growth, improved GAAP net loss, but worsening adjusted net loss, alongside strategic restructuring and ongoing FDA discussions for DrugSorb-ATR.

Summary

• Full year 2025 revenue increased 4% to $37.1 million, though it was flat on a constant currency basis compared to $35.6 million in 2024.
• Gross margin for 2025 expanded to 71% from 70% in 2024.
• Operating loss improved by 10% to $14.7 million in 2025, down from $16.5 million in 2024.
• Net loss significantly improved to $8.2 million ($0.13 per share) in 2025, compared to $20.7 million ($0.38 per share) in 2024.
• Adjusted net loss for 2025 worsened to $14.2 million ($0.23 per share) from $12.7 million ($0.23 per share) in 2024.
• Adjusted EBITDA loss improved to $10.5 million in 2025 from $11.5 million in 2024.
• Fourth quarter 2025 revenue was $9.2 million, up 1% year-over-year but down 8% on a constant currency basis.
• Q4 2025 gross margin expanded to 74% from 70% in Q4 2024.
• Q4 2025 operating loss worsened to $4.6 million, including a $0.5 million restructuring charge, compared to $3.7 million in Q4 2024.
• Q4 2025 adjusted net loss worsened to $4.3 million ($0.07 per share) from $1.7 million ($0.03 per share) in Q4 2024, which included a $1.7 million tax benefit.
• Total cash, cash equivalents, and restricted cash stood at $7.8 million on December 31, 2025, a decrease from $9.1 million on September 30, 2025.
• The company implemented a strategic workforce and cost reduction program in Q4 2025, reducing headcount by 10% to accelerate cash flow breakeven to the second half of 2026.
• Over 300,000 cumulative CytoSorb treatments have been delivered globally, an increase of more than 50% over the past few years.
• Ongoing interactive discussions with the FDA are taking place to determine the content and timing of a new De Novo application for DrugSorb-ATR, following an appeal denial in August 2025.
• The company secured an additional $2.5 million from an amended credit facility in November 2025 and extended the interest-only period on its term loan through the end of 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, with positive clinical and strategic advancements balanced by mixed financial performance, particularly in adjusted metrics and Q4, and ongoing regulatory hurdles for a key product. The path to cash flow breakeven in H2 2026 is a critical future determinant.

Positives

• Full year 2025 revenue increased by 4% to $37.1 million.
• Full year 2025 gross margin expanded to 71%, up from 70% in 2024.
• Operating loss for 2025 improved by 10% to $14.7 million.
• Net loss for 2025 significantly improved to $8.2 million from $20.7 million in 2024.
• Adjusted EBITDA loss for 2025 improved to $10.5 million from $11.5 million in 2024.
• Direct sales outside of Germany increased by 13.0% to $8.6 million, and distributor sales increased by 11.4% to $16.5 million.
• Achieved a key milestone of over 300,000 cumulative CytoSorb treatments globally, representing more than a 50% increase over the past few years.
• Strong and growing body of clinical evidence supports CytoSorb's use in sepsis, acute liver failure, cardiogenic shock, and cardiac surgery.
• Successfully scaled up distribution of PuriFi hemoperfusion pumps, with over 100 placed internationally.
• Launched HotSwap, an EU-approved solution for rapid and seamless exchange of CytoSorb cartridges.
• FDA confirmed no concerns regarding device safety for DrugSorb-ATR during the appeal process.
• Pivotal STAR-T trial results for DrugSorb-ATR were published, concluding it is safe and can reduce bleeding severity.
• Secured an additional $2.5 million from an amended credit facility in November 2025, enhancing balance sheet flexibility.
• Extended the interest-only period on the term loan through the end of 2026.
• Implemented a strategic workforce and cost reduction program, reducing headcount by 10% to accelerate timing to cash flow breakeven.

Negatives

• Full year 2025 revenue was flat on a constant currency basis.
• Germany sales decreased by 10% to $11.8 million due to restructuring.
• Fourth quarter 2025 revenue was down 8% on a constant currency basis.
• Fourth quarter 2025 operating loss worsened to $4.6 million, including a $0.5 million restructuring charge, compared to $3.7 million in Q4 2024.
• Adjusted net loss for 2025 worsened to $14.2 million from $12.7 million in 2024.
• Fourth quarter 2025 adjusted net loss worsened to $4.3 million from $1.7 million in Q4 2024.
• Fourth quarter 2025 adjusted EBITDA loss worsened to $3.2 million compared to $2.4 million in Q4 2024.
• Total cash, cash equivalents, and restricted cash decreased to $7.8 million on December 31, 2025, from $9.1 million on September 30, 2025.
• The initial De Novo application for DrugSorb-ATR was denied by the FDA in April 2025, and the denial was upheld on appeal in August 2025, citing the need for additional information for the proposed label indication.

Risks

• The restructuring of the direct sales team and strategy in Germany may not achieve expected growth or could face further challenges.
• Uncertainty in obtaining U.S. FDA and Health Canada regulatory approval and marketing authorization for DrugSorb-ATR.
• Failure to successfully complete the strategic workforce and cost reduction plan, which could impact the ability to reduce costs, optimize operations, and achieve cash-flow break-even in the second half of 2026.
• Challenges in appropriately financing the Company to support ongoing operations and growth initiatives.
• General business risks as discussed in the Annual Report on Form 10-K filed with the SEC on March 31, 2025, and subsequent Quarterly Reports on Form 10-Q.

Future Outlook

The company anticipates achieving cash flow breakeven in the second half of 2026, supported by a strategic workforce and cost reduction program implemented in Q4 2025. Management expects to drive growth across all CytoSorb sales channels and continue advancing FDA De Novo authorization for DrugSorb-ATR to establish a second engine of revenue growth. Further updates on the anticipated timing of the DrugSorb-ATR submission are expected once final FDA requirements are established, with a typical regulatory decision within a 150-day review period post-submission.

Management Comments

• "2025 was a transitional year for our business as we made good progress in four key objectives. We ended the year with positive clinical and commercial momentum for 2026, with a lower cost structure and improved balance sheet to support our growth."
• "We continue to make progress with the FDA to align on the content and timing of a new De Novo submission for DrugSorb-ATR and look forward to providing further updates in the future."
• "Our core business outside of Germany delivered healthy growth in 2025, driven by a growing body of clinical data supporting the use of CytoSorb across multiple applications, along with encouraging early progress from initiatives such as the PuriFi pump."
• "We are also seeing objective signs that our turnaround plan in Germany is beginning to deliver operational improvements."
• "As we look ahead to the remainder of 2026, we are focused on driving growth across all CytoSorb sales channels, achieving cash flow breakeven in the second half of the year, and continuing to advance FDA De Novo authorization for DrugSorb-ATR to establish a second engine of revenue growth."

Industry Context

StockSavvy.ai notes that CytoSorbents operates in the critical care and cardiac surgery markets, addressing life-threatening conditions through blood purification. The company's focus on sepsis and antithrombotic removal aligns with significant unmet medical needs. The withdrawal of AstraZeneca's Andexxa from the U.S. market in December 2025 for direct oral anticoagulant reversal creates a potential void that DrugSorb-ATR could partially fill, if approved. The increasing availability of generic ticagrelor is expected to boost its usage, further amplifying the need for effective reversal strategies, which could benefit DrugSorb-ATR's market adoption. The continued generation of clinical evidence for CytoSorb in various critical conditions positions the company to capitalize on growing awareness and adoption of blood purification therapies.

Comparison to Industry Standards

• The company's achievement of over 300,000 cumulative CytoSorb treatments globally, with a 50% increase in recent years, demonstrates a growing adoption rate for its therapy, comparable to other established medical devices gaining traction in critical care settings.
• The multinational survey endorsed by ESICM and SIAARTI, identifying broad-spectrum hemoadsorption like CytoSorb as the most commonly used and preferred modality (43%) for refractory septic shock, suggests a strong competitive position against other extracorporeal blood purification methods.
• The consistent findings from the STAR-T trial and STAR Registry, demonstrating DrugSorb-ATR's ability to reduce perioperative bleeding risk in patients on antithrombotic therapies, align with the industry's push for improved patient safety and reduced complications in cardiac surgery, potentially offering a differentiated solution compared to pharmacological reversal agents or standard care.
• The reported improvements in hemodynamics, reduced vasopressor needs, and lower in-hospital mortality (p=0.04) and 28-30 day mortality (p=0.003) with CytoSorb use in sepsis, as shown in a meta-analysis of 449 CytoSorb-treated patients vs. 295 controls, indicate clinical efficacy that is competitive with or superior to existing supportive care strategies for this high-mortality condition.

Stakeholder Impact

• Shareholders: Potential for future value creation if DrugSorb-ATR gains FDA approval and the company achieves cash flow breakeven, but current mixed financial results and regulatory delays introduce uncertainty.
• Employees: Impacted by the 10% workforce reduction implemented in Q4 2025 as part of the cost reduction program.
• Customers (Healthcare Providers): Benefit from continued clinical evidence supporting CytoSorb's efficacy and the introduction of new products like PuriFi pumps and HotSwap for improved therapy delivery.
• Creditors: The amended credit facility and extended interest-only period provide some financial stability and flexibility.

Next Steps

• Provide further updates on the anticipated timing of the new DrugSorb-ATR De Novo submission once final FDA requirements are established.
• Drive growth across all CytoSorb sales channels, leveraging growing clinical evidence and new initiatives like the PuriFi pump.
• Achieve cash flow breakeven in the second half of 2026 through continued cost reduction and operational efficiencies.
• Advance FDA De Novo authorization for DrugSorb-ATR to establish it as a second engine of revenue growth.
• Present new analyses and data at major cardiovascular conferences, including EuroPCR in May 2026, ESC Congress in August 2026, and EACTS Annual Meeting in October 2026.

Key Dates

Recommendation

The company is in a transitional phase, demonstrating some positive operational and clinical momentum, particularly with CytoSorb's growing adoption and supporting data. However, the mixed financial results, especially the worsening adjusted net loss and Q4 performance, coupled with the ongoing regulatory delays for the critical DrugSorb-ATR product, create a balanced risk-reward profile. The commitment to achieving cash flow breakeven in H2 2026 is a key future catalyst. A seasoned investor would likely hold to monitor the progress on FDA approval for DrugSorb-ATR and the effectiveness of the cost reduction and growth strategies in achieving sustained profitability.

Keywords

CytoSorbents, CTSO, Blood Purification, Sepsis, Septic Shock, Cardiac Surgery, DrugSorb-ATR, FDA Approval, De Novo Application, Financial Results, Revenue, Net Loss, EBITDA, Cash Flow Breakeven, Medical Device, Critical Care, Antithrombotic Removal, Ticagrelor, Rivaroxaban, Apixaban